Research programme: immunological disorders therapy - ShionogiAlternative Names: S-2678
Latest Information Update: 20 Aug 2010
At a glance
- Originator Shionogi
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Transplant rejection
Most Recent Events
- 25 Oct 2005 Preclinical trials in Transplant rejection in Japan (unspecified route)
- 25 Oct 2005 Preclinical trials in Cancer in Japan (unspecified route)